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Introduction and objectives: Metastatic penile squamous cell carcinoma (PSCC) is
associated with dismal outcomes with median overall survival (OS) of 6–12 months in
the first-line and <6 months in the salvage setting. Given the rarity of this disease,
randomized trials are difficult. Prognostic risk models may assist in rational drug
development by comparing observed outcomes in nonrandomized phase II studies
and retrospective data vs. predicted outcomes based on baseline prognostic factors
in the context of historically used agents. In this retrospective study, we constructed
a prognostic model in the salvage setting of PSCC patients receiving second or later
line systemic treatment, and also explored differences in outcomes based on type of
treatment.
Materials and methods : We performed a chart review to identify patients with locally
advanced unresectable or metastatic PSCC who received second or later line systemic
treatment in centers from North America and Europe. The primary outcome was OS
from initiation of treatment, with secondary outcomes being progression-free survival
(PFS) and response rate (RR). OS was estimated using the Kaplan-Meier method. Cox
proportional hazards regression was used to identify prognostic factors for outcomes
using univariable and multivariable models.
Results: Sixty-five patients were eligible. Seventeen of 63 evaluable patients had a
response (27.0%, 95% confidence interval [CI] = 16.6–39.7%) and median OS and PFS
were 20 (95% CI = 20–21) and 12 (95% CI = 12, 16) weeks, respectively. Visceral
metastasis (VM) and hemoglobin (Hb) ≤ 10 gm/dl were consistently significant poor
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prognostic factors for both OS and PFS, and Hb was also prognostic for response.
The 28 patients with neither risk factor had a median OS (95% CI) of 24 (20–40) weeks
and 1-year (95% CI) OS of 13.7% (4.4–42.7%), while the 37 patients with 1 or 2 risk
factors had median OS (95% CI) of 20 (16–20) weeks and 1-year (95% CI) OS of 6.7%
(1.8–24.9%). Cetuximab-including regimens were associated with a trend for improved
RR compared to other agents (Odds ratio = 5.05, 95% CI = 0.84–30.37, p = 0.077).
Taxanes vs. non-taxane, and combination vs. single agent therapy was not associated
with improved outcomes. The study is limited by its modest sample size.
Conclusion: This is the first prognostic classification proposed for patients receiving
salvage systemic therapy for advanced PSCC. The presence of VM and Hb ≤ 10 gm/dl
was associated with poor OS and PFS. Cetuximab appeared to be associated with
better RR. This prognostic model may assist in salvage therapy drug development for this
orphan disease by improving interpretation of outcomes seen in nonrandomized data.
Keywords: penile squamous cell carcinoma, salvage, prognosis, classification
INTRODUCTION
In developed countries, penile squamous cell carcinoma (PSCC)
is relatively rare, but less developed countries exhibit higher
incidences. In 2016, approximately 2000 new cases and 300
deaths from penile cancers were predicted to occur in the United
States (Sonpavde et al., 2013; Siegel et al., 2016). Although most
patients present with localized disease, locoregional unresectable,
or metastatic relapses are common after radical treatment
based on surgery and/or radiotherapy. PSCC patients with
metastatic disease have a poor prognosis, with a median overall
survival (OS) in the range of 6–12 months using platinum-based
combination chemotherapy in published retrospective studies
(Theodore et al., 2008; Di Lorenzo et al., 2012; Zhang et al., 2015).
Patients with progressive disease following prior chemotherapy
have dismal outcomes with OS <6 months (Di Lorenzo et al.,
2011).
Prognostic nomograms have been reported in patients with
localized disease undergoing surgery (Kattan et al., 2006) and
also in patients with metastatic disease receiving first-line
systemic treatment (Pond et al., 2014), Unfortunately, there is
a lack of such prognostic classifications for patients receiving
second or later-line salvage systemic treatment for advanced
penile cancer, i.e., locally advanced unresectable or metastatic
disease. Prognostic classifications/models may be useful for
the interpretation of phase II trial outcomes, especially in the
particular case of penile carcinoma, since the rarity of the disease
makes it difficult to conduct large, randomized-controlled trials.
Moreover, salvage regimens may be tailored for the patient
population, e.g., those with particularly dismal outcomes may
warrant the evaluation ofmore aggressive combination regimens.
This retrospective review was therefore conducted with an
aim of identifying prognostic factors for patient outcomes,
notably survival, amongst patients with PSCC receiving salvage
systemic therapy. After identifying prognostic factors, it was
desired to construct a prognostic model which could be used
for risk stratifying patients. In addition, a secondary aim of this
study was to explore for differences between salvage treatments,
in particular anti-epidermal growth factor receptor (EGFR)
containing vs. non anti-EGFR containing therapy.
MATERIALS AND METHODS
Patient Population
A retrospective chart review was performed in order to identify
patients with locally advanced unresectable or metastatic PSCC
who received second or later lines of systemic treatment in
referral medical centers from North America, Europe, and
Japan. Eligible patients were men receiving systemic treatment
(but not concurrent chemo-radiotherapy or adjuvant treatment)
for locally advanced unresectable or metastatic disease or
neoadjuvant therapy preceding definitive local therapy after
being treated with ≥1 systemic treatments for locally advanced
unresectable or metastatic disease or neoadjuvant therapy
preceding definitive local therapy. Patients who received adjuvant
therapy following local definitive therapy and concurrent
systemic therapy and radiation as the only prior systemic
treatment were excluded.
The following patient and disease characteristics at baseline
were requested: Eastern Cooperative Oncology Group (ECOG)
performance status (PS), American Joint Committee on Cancer
7th Edition clinical stage, sites of metastases (soft tissue
vs. visceral), hemoglobin, race, smoking status, circumcision
status, peripheral blood neutrophil count, peripheral blood
lymphocyte count, albumin, family history of penile cancer,
history of precancerous lesion, human immunodeficiency virus
(HIV) status, lymphovascular invasion (LVI), histologic subtype,
systemic therapy regimen, postchemotherapy surgery received,
time from last prior therapy, number of previous lines received
(measured including biologic and chemotherapy ± radiation),
time to objective tumor progression, time to last follow-up, and
radiological best response.
Statistical Methods
Summary statistics were used to describe the patient, tumor,
and treatment characteristics, as well as outcomes. The primary
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outcome was overall survival, with secondary outcomes being
progression-free survival and response rate. Descriptive statistics
were used to summarize patient and tumor information, as well
as outcomes. Survival was defined as the time from initiation of
salvage systemic treatment until death due to any cause, while
progression-free survival (PFS) was defined as the time from
initiation of salvage systemic treatment until disease progression
(clinical or radiological) as defined in the patients chart. Any
patient without death or progression event was censored at the
last chart entry. Response was defined using the RECIST criteria
(Therasse et al., 2000).
The Kaplan-Meier method was used to estimate time to event
outcomes (OS and PFS). Cox proportional hazards regression
and logistic regression were used to explore factors potentially
prognostic of time to event outcomes and response respectively.
Each factor was examined in univariate models. Stepwise
selection was initially used for constructing a multivariable
model, with backward and forward selection processes used to
explore the robustness of thismodel. Owing to themodest sample
size, clinical and statistical expertise was then used to create a final
prognostic model.
Some factors with little variability (e.g., family history, HIV
status) along with factors having a lot of missing data or unknown
information (e.g., HPV status) were excluded from being a
potential candidate in the multivariate model. Transformations
(e.g., using a logarithmic transformation for non-normal data)
or categorization (e.g., number of prior lines of treatment) was
also performed for statistical purposes. All tests were two-sided
and statistical significance was defined as a p-value of 0.05 or less
throughout.
This retrospective review study was conducted according
to the existing privacy laws by using anonymized records
and according to the Declaration of Helsinki. The protocol
was reviewed and approved by the institutional review
board/independent ethics committee of the Institutions
that requested to do so according to local laws and policies.
RESULTS
Patient Characteristics and Treatment
Outcomes
Sixty-five patients treated at 8 participating Institutions were
available for the analysis (Table 1). The median OS was 20 (95%
CI = 20–21) weeks, while the median PFS was 12 (95% CI =
12–16) weeks (Table 2). Prior cisplatin had been administered
to 52 patients (80%) and most patients had stage 4 disease
(N = 53, 81.5%), with visceral disease in 30 patients (46.2%).
Treatment regimens administered included a taxane agent in
48 patients (73.8%) and cetuximab in 17 patients (26.2%).
Five patients received either bleomycin/methotrexate/cisplatin,
single agent capecitabine, cisplatin/5FU, gemcitabine/navelbine,
or Methotrexate/bleomycin, respectively, while single-agent
gemcitabine was administered to 4 patients. Most patients had
ECOG-PS 0-1 (N = 52, 82.6%) and were of Caucasian race
(N = 59, 90.8%). Seventeen of 63 evaluable patients had a
response (27.0%, 95% confidence interval [CI]= 16.6–39.7%).
TABLE 1 | Patients’ characteristics.
Characteristic Statistic N Result
Age Mean (std dev) 65 61.3 (8.7)
Hemoglobin, g/dL Mean (std dev) 64 11.7 (1.6)
Neutrophils, /mm3 Median (range) 63 4000 (2100, 21000)
Lymphocytes, /mm3 Median (range) 62 1055 (400, 2100)
Neutrophils-Lymphocytes
Ratio
Median (range) 62 3.8 (1.6, 17.5)
≥5 21 (33.9)
Albumin, g/dL Mean (std dev) 60 3.47 (0.54)
Time from prior treatment,
weeks
Median (range) 64 20 (4, 176)
Smoking status Never 64 16 (25.0)
Past smoker 29 (45.3)
Current smoker 19 (29.7)
Circumcision No 60 49 (81.7)
Yes, Postnatal 8 (13.3)
Yes, Neonatal 3 (5.0)
ECOG status 0 63 26 (41.3)
1 26 (41.3)
11 (17.5)
2
Race Caucasian 65 59 (90.8)
Hispanic/Latin
American
6 (9.2)
Family history None 65 63 (96.9)
Other than 1st
degree relative
2 (3.1)
Prior history of
precancerous lesion
Yes 65 22 (33.9)
HPV status Yes 33 18 (54.5)
HIV status Yes 63 1 (1.6)
Stage IV 65 53 (81.5)
Visceral disease Yes 65 30 (46.2)
Lymph-vascular invasion Yes 14 11 (78.6)
Prior cisplatin-based
chemotherapy
Yes 65 52 (80.0)
Prior lines of treatment 1 65 37 (56.9)
2 8 (12.3)
3 20 (30.8)
Agent Paclitaxel/carboplatin 1
Docetaxel 3
Paclitaxel 30
Paclitaxel/ifosfamide/
cisplatin
1
Bleomycin/methotrexate/
cisplatin
1
Capecitabine 1
Cetuximab 8
Cetuximab/docetaxel 6
Cisplatin/5FU 1
Gemcitabine 4
Gemcitabine/navelbine 1
Methotrexate/bleomycin 1
(Continued)
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TABLE 1 | Continued
Characteristic Statistic N Result
Paclitaxel/5FU 2
Paclitaxel/carboplatin/
cetuximab
1
Paclitaxel/cetuximab 2
Paclitaxel/cisplatin/gemcitabine 1
Includes Cetuximab 17 (26.2)
Includes a taxane 48
TABLE 2 | Patients’ outcomes.
Outcomes
Best response (RECIST) Complete Response 63 2 (3.2)
Partial Response 15 (23.8)
Stable Disease 16 (25.4)
Progressive Disease 30 (47.6)
Progression-free survival N (%) Events 64 62 (96.9)
Median (95% CI) Weeks 12 (12, 16)
6-month (95% CI) PFS 10.9 (4.8, 19.9)
1-year (95% CI) PFS 3.6 (0.7, 10.9)
Overall survival N (%) Deaths 65 55 (84.6)
Median (95% CI) Weeks 20 (20, 21)
6-month (95% CI) OS 28.2 (17.5, 39.9)
1-year (95% CI) OS 9.9 (3.5, 20.1)
Univariable Analyses Examining
Association of Variables with Outcomes
Tables 3–5 show the univariable results from Cox and logistic
regression models assessing the prognostic ability of factors
for OS, PFS and response respectively. Age (hazard ratio
[HR]/decade = 1.48, 95% CI = 1.09–2.00, p = 0.011), low
hemoglobin (HR = 0.76, 95% CI = 0.62–0.95, p = 0.014),
low lymphocytes (HR/100 mm3 = 0.91, 95% CI = 0.84–0.98,
p = 0.015), and prior non-cisplatin-based chemotherapy (HR
= 2.08, 95% CI = 1.08–4.17, p = 0.029) were all significantly
prognostic for poor OS in univariable models (Table 3). Age,
anemia and visceral disease were also significantly associated with
poor PFS on univariable analyses (Table 4). Higher hemoglobin
and albumin levels, better ECOG-PS and cetuximab were
associated with better odds of response to systemic treatment
(Table 5).
Multivariable Analyses Examining
Association of Variables with Clinical
Outcomes
Visceral disease (HR = 1.56, 95% CI = 0.90–2.70, p = 0.11)
and number of lymphocytes (HR/100mm3 = 0.91, 95% CI =
0.84–0.99, p = 0.023) were the variables retained in the model
after the stepwise selection. Visceral disease (HR = 1.77, 95%
CI = 1.06–2.95, p = 0.030) was the only prognostic factor
TABLE 3 | Prognostic factors of overall survival.
Characteristic Units Hazard ratio (95% CI) p-value
Age per decade 1.48 (1.09, 2.00) 0.011
Hemoglobin, g/dL per g/dL 0.76 (0.62, 0.95) 0.014
Neutrophils, /mm3 Log-transformed 0.90 (0.53, 1.52) 0.69
Lymphocytes, /mm3 per 100 mm3 0.91 (0.84, 0.98) 0.015
Neutrophils-Lymphocytes
Ratio
≥5 vs. <5 0.81 (0.45, 1.45) 0.47
Albumin, g/dL per g/dL 0.70 (0.38, 1.26) 0.23
Time from prior treatment,
weeks
Log-transformed 1.08 (0.75, 1.54) 0.69
Smoking status Never 0.98 (0.46, 2.10) 0.11
Past Smoker 1.78 (0.92, 3.41)
Current Smoker REFERENCE
Circumcision Yes vs. No 1.31 (0.65, 2.64) 0.45
ECOG status 0 0.75 (0.34, 1.63) 0.76
1 0.85 (0.39, 1.85)
2 REFERENCE
Race Caucasian vs.
Hispanic
0.91 (0.35, 2.34) 0.84
Family history Other vs. None 0.41 (0.10, 1.70) 0.22
Prior history of
precancerous lesion
Yes vs. No 1.33 (0.76, 2.33) 0.31
HPV status Yes vs. No 1.48 (0.72, 3.03) 0.29
HIV status Yes vs. No 1.23 (0.17, 8.99) 0.84
Stage IV vs. III 1.90 (0.89, 4.06) 0.096
Visceral disease Yes vs. No 1.63 (0.95, 2.80) 0.076
Lymph-vascular invasion Yes vs. No 0.73 (0.14, 3.67) 0.70
Prior cisplatin-based
chemotherapy
Yes vs. No 0.48 (0.24, 0.93) 0.029
Prior lines of treatment ≥2 vs. 1 0.93 (0.54, 1.61) 0.80
Cetuximab Yes vs. No 1.15 (0.63, 2.09) 0.65
of poor PFS. Higher hemoglobin levels (OR = 2.75 per each
g/dL increase, 95% CI = 1.44–5.25, p = 0.002) and cetuximab-
containing treatment regimen (OR = 5.86 for cetuximab-
containing regimen versus no cetuximab, 95% CI = 1.35–25.47,
p= 0.019) were prognostic factors for response.
Based on the results of the stepwise selection along with
clinical and statistical expertise, a 3-factor model, including
anemia status, visceral disease status and lymphocytes, was
proposed. However, after adjusting for the other 2 factors,
number of lymphocytes was deemed to not add statistically
important information as a prognostic factor for OS (p= 0.076),
PFS (p = 0.78) nor response (p = 0.082). Thus, a two-factor
prognosticmodel for OSwas ultimately proposed. Amongst these
patients, having visceral disease (HR = 2.06, 95% CI = 1.18–
3.59, p = 0.011) was associated with worse prognosis, while
higher hemoglobin levels were associated with decreased risk of
death (HR = 0.73 per g/dL, 95% CI = 0.58–0.91, p = 0.006).
Similar results were observed for PFS, with visceral disease being
associated with increased risk of progression (HR = 2.01, 95%
CI = 1.18–3.43, p = 0.010) and higher hemoglobin levels being
associated with decreased risk of progression (HR = 0.78 per
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TABLE 4 | predictive factors of progression-free survival.
Characteristic Units Hazard ratio (95% CI) p-value
Age per decade 1.39 (1.02, 1.89) 0.035
Hemoglobin, g/dL per g/dL 0.82 (0.68, 0.99) 0.041
Neutrophils, /mm3 Log-transformed 1.21 (0.75, 1.94) 0.43
Lymphocytes, /mm3 per 100 mm3 0.99 (0.92, 1.06) 0.70
Neutrophils-lymphocytes
ratio
≥5 vs. <5 0.80 (0.47, 1.38) 0.43
Albumin, g/dL per g/dL 0.60 (0.33, 1.09) 0.092
Time from prior treatment,
weeks
Log-transformed 1.02 (0.72, 1.44) 0.92
Smoking status Never 1.16 (0.57, 2.35) 0.26
Past Smoker 1.63 (0.87, 3.05)
Current Smoker REFERENCE
Circumcision Yes vs. No 1.07 (0.55, 2.08) 0.83
ECOG status 0 0.76 (0.37, 1.57) 0.74
1 0.88 (0.43, 1.80)
2 REFERENCE
Race Caucasian vs.
Hispanic
0.51 (0.21, 1.19) 0.12
Family history Other vs None 0.23 (0.05, 1.02) 0.054
Prior history of
precancerous lesion
Yes vs. No 1.12 (0.66, 1.89) 0.67
HPV status Yes vs. No 1.47 (0.70, 3.09) 0.31
HIV status Yes vs. No 0.70 (0.10, 5.09) 0.72
Stage IV vs. III 1.28 (0.68, 2.42) 0.45
Visceral disease Yes vs. No 1.77 (1.06, 2.95) 0.030
Lymph-vascular invasion Yes vs. No 0.54 (0.13, 2.24) 0.39
Prior cisplatin-based
chemotherapy
Yes vs. No 0.96 (0.51, 1.81) 0.90
Prior lines of treatment ≥2 vs. 1 1.04 (0.62, 1.72) 0.90
Cetuximab Yes vs. No 0.95 (0.54, 1.67) 0.86
each g/dL increase, 95% CI = 0.62–0.95, p = 0.015). Higher
hemoglobin levels were also associated with increased odds of
having a radiologic response (OR = 2.45, 95% CI = 1.38–4.36,
p= 0.002).
Prognostic Stratification
Patients were considered as having a risk factor if they had
visceral disease or hemoglobin levels Hb ≤ 10 g/dL). There
were 28, 33, and 4 patients with 0, 1, and 2 risk factors.
Given the small sample size, patients with 1 and 2 risk factors
were combined. The 28 patients with neither risk factor had
a median OS of 24 (95% CI: 20–40) weeks, and 6-month
and 1-year OS of 47.2% (95% CI: 31.5–70.8%) and 13.7%
(4.4–42.7%), see Figure 1. In comparison, the 37 patients with
1 or 2 risk factors had median OS of 20 (95% CI: 16–
20) weeks, 6-month and 1-year OS of 13.4% (95% CI: 5.6–
32.1%) and 6.7% (95%: 1.8–24.9%). The difference did achieve
statistical significance (p = 0.0049). Of evaluable patients with
0 and 1–2 risk factors, 9/26 (34.6%) and 8/37 (21.6%) had a
response.
TABLE 5 | Predictive factors of response.
Characteristic Units Odds ratio (95% CI) p-value
Age per decade 0.67 (0.35, 1.28) 0.23
Hemoglobin, g/dL per g/dL 2.43 (1.37, 4.29) 0.002
Neutrophils, /mm3 Log-transformed 0.31 (0.08, 1.14) 0.078
Lymphocytes, /mm3 per 100 mm3 0.98 (0.83, 1.16) 0.83
Neutrophils-lymphocytes
ratio
≥5 vs. <5 3.36 (0.84, 13.44) 0.087
Albumin, g/dL per g/dL 4.82 (1.39, 16.72) 0.013
Time from prior treatment,
weeks
Log-transformed 0.80 (0.36, 1.79) 0.59
Smoking status Never 4.50 (0.75, 26.92) 0.24
Past Smoker 3.37 (0.63, 17.96)
Current Smoker REFERENCE
Circumcision Yes vs. No 1.72 (0.43, 6.89) 0.45
ECOG status 0 7.86 (0.87, 71.06) 0.036
1 1.82 (0.18, 18.41)
2 REFERENCE
Race Caucasian vs.
Hispanic
1.95 (0.21, 18.03) 0.56
Family history Other vs. None 0.36 (0.02, 6.02) 0.47
Prior history of precancerous
lesion
Yes vs. No 0.48 (0.14, 1.70) 0.25
HPV status Yes vs. No 2.00 (0.40, 9.91) 0.40
HIV status Yes vs. No Not Calculable –
Stage IV vs. III 1.14 (0.27, 4.81) 0.86
Visceral disease Yes vs. No 0.97 (0.32, 2.96) 0.96
Lymph-vascular invasion Yes vs. No Not Calculable –
Prior cisplatin-based
chemotherapy
Yes vs. No 2.08 (0.41, 10.67) 0.38
Prior lines of treatment ≥2 vs. 1 0.65 (0.21, 2.05) 0.46
Cetuximab-containing
regimen
Yes vs. No 3.65 (1.10, 12.12) 0.034
DISCUSSION
In this multi-institutional retrospective study cohort, systemic
therapy after failure of primary cisplatin-based therapy was
associated with limited disease control. Median PFS and OS
were 12 and 20 weeks, respectively, with about 90% of patients
progressing and dying within 6 months and 1 year, respectively.
Our results are consistent with those recently published in a
smaller study by Wang et al. that analyzed outcomes of 19
patients treated with local or systemic therapy for recurrent
PSCC after neoadjuvant paclitaxel, ifosfamide, and cisplatin
chemotherapy (Wang et al., 2015). We also constructed a
prognostic model including visceral disease status and Hb
level which discriminated patients into statistically significantly
different groups. However, our study is limited by small sample
size of only 65 patients. Some candidates for prognostic factors
such as stage, ECOG-PS, albumin, HPV status and number of
prior regimens were not independently prognostic, possibly due
to the modest sample size.
It is noteworthy that in our retrospective study cohort, the
95% CI interval for OS was 20–21 weeks, which implies that the
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FIGURE 1 | Survival based on number of prognostic factors*.
*Prognostic factors included are visceral metastasis and hemoglobin ≤10.
prognosis of our cohort population was homogeneously poor.
The negative prognostic value of visceral disease observed in this
study was consistent with a previously published retrospective
analysis of 140 patients with penile squamous cell carcinoma
receiving first-line systemic therapy, which showed visceral
disease had an increased hazard ratio for death of 2.42 (95%
CI: 1.47–4.00) (Pond et al., 2014). Also, in a study including
26 patients treated with concurrent chemo-radiotherapy for
advanced penile cancer, a trend for a detrimental prognostic
effect of visceral disease was reported (HR = 3.35; 95%
CI: 0.69–16.21; P = 0.13). Indeed, a prognostic classification
recently proposed in the first-line setting of advanced PSCC
receiving cisplatin-based chemotherapy included one clinical
factor, visceral disease, and one tumor tissue molecular factor,
MAML2 gene expression (Necchi et al., 2016a).
Incorporating clinical judgment, we proposed a two-variable
based risk group classification based on VM (absent vs. present)
and baseline hemoglobin levels (≤10 vs. >10). These factors
may provide a simple prognostic classification tool useful for
clinical practice and for patient selection/stratification criteria for
research purposes, pending their external validation.
Of note, our study cohort included 17 patients treated with
cetuximab, which was administered either alone (8 patients) or in
combination with a taxane/platinum agent (9 patients). Evidence
of activity of anti-EGFR agents in advanced penile cancer was
originally reported when administered as single agent (Necchi
et al., 2016b) or in combination with chemotherapy (Rescigno
et al., 2012). In a literature review of individual data of 28 patients
with advanced penile cancer receiving anti-EGFR monoclonal
antibodies (cetuximab, panitumumab, and nimotuzumab), a 50%
radiological response rate was achieved, but a median PFS of
only approximately 3 months (interquartile range, 1.5–5.78,
Di Lorenzo et al., 2015). From a biological perspective, EGFR
appears a promising target in penile cancer, as it is universally
expressed and frequently phosphorylated (Di Lorenzo et al.,
2013a), but infrequently amplified (Di Lorenzo et al., 2013a),
or mutated (Di Lorenzo et al., 2013b),while mutations of
downstream signaling proteins (such as KRAS/BRAF) are rare
(Gou et al., 2013). Nevertheless, we failed to identify a signal of
prolonged OS associated with the use of cetuximab in our study
cohort. The use of anti-EGFR agents may be most beneficial in
patients requiring tumor shrinking (e.g., symptomatic metastatic
patients or patients receiving neoadjuvant treatment, Luo et al.,
2015). Ongoing phase II trials are evaluating dacomitinib and
afatinib, oral pan-Her inhibitors, as neoadjuvant or salvage
therapy for PSCC.
Finally, the association of a higher baseline lymphocyte
count with improved OS outcomes is intriguing, although the
final proposed model does not include this variable. Kasuga
et al. (2016) found that a higher baseline neutrophil to
lymphocyte ratio was associated with increased disease specific
mortality in patients with penile cancer. Interestingly, increased
lymphocyte baseline count was associated with improved
prognosis inmultiplemalignancies, includingmelanoma patients
treated with pembrolizumab, an anti-programmed death (PD)-1
immunotherapeutic agent (Weide et al., 2016). On the grounds of
the association of PD-L1 tumor expression with response to anti-
PD-1 agents in solid malignancies (melanoma, non-small cell
lung cancer) (Di Lorenzo et al., 2016) and of PD-L-1 expression
in penile cancer patients (Udager et al., 2016), pembrolizumab
will be tested in a single-arm phase II study (ClinicalTrials.gov
Identifier: NCT02837042) in PSCC patients. In such a population
of PSCC treated with immunotherapy, the prognostic value of
baseline lymphocyte count may be clinically relevant.
To summarize, we have proposed the first prognostic
classification for patients receiving salvage systemic therapy for
advanced PSCC, which can enhance interpretation of outcomes
seen in nonrandomized salvage therapy data. The presence
of visceral disease and Hb ≤ 10 gm/dl was associated with
poor OS and PFS. A signal for incremental survival benefit
with cetuximab was not confirmed in spite of an apparently
improved response rate. This prognostic model is a first step
toward prognostic classification in this setting. Analysis of
a larger dataset incorporating clinical and molecular factors
may further optimize prognostic classification for this orphan
disease and provide insights regarding potential therapeutic
targets.
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